Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro

Biomaterials

Volumn 31, Issue 22, 2010, Pages 5741-5748

  Adam, Albert ^a   Montpas, Nicolas ^a   Keire, David ^b   Désormeaux, Anik ^a   Brown, Nancy J ^c   Marceau, François ^d   Westenberger, Benjamin ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

Anaphylactoid reaction; Bradykinin; Heparin; Oversulfated chondroitin sulfate

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME INHIBITORS; CHONDROITIN SULFATES; CONCENTRATION OF; CONTACT SYSTEMS; DEXTRAN SULFATES; FOOD AND DRUG ADMINISTRATION; HUMAN PLASMAS; IN-VITRO; PATHOPHYSIOLOGY;

CHEMICAL ACTIVATION; CONCENTRATION (PROCESS); CONTAMINATION; GLUCOSE; PLASMA (HUMAN); PLASMAS; SULFUR COMPOUNDS;

POLYSACCHARIDES;

BIOMATERIAL; BRADYKININ; CHONDROITIN SULFATE; HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE 1;

ANAPHYLAXIS; ARTICLE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; INCUBATION TIME; KINETICS; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANAPHYLAXIS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; BRADYKININ; CHONDROITIN SULFATES; DRUG CONTAMINATION; HEPARIN; HUMANS; PLASMA;

EID: 77953063429     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.03.074     Document Type: Article

References (38)

1. Acute allergic-type reactions among patients undergoing hemodialysis-multiple states, 2007-2008. MMWR Morb Mortal Wkly Rep 2008, 57(5):124-125.
2. Laurencin C.T., Nair L. The FDA and safety-beyond the heparin crisis. Nat Biotechnol 2008, 26(6):621-623.
3. U.S.Department of Health & Human Services U.S. food and drug administration. Information on adverse event reports and heparin Online. 2009 November. Available from URL:. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM112669.
4. Tielemans C., Madhoun P., Lenaers M., Schandene L., Goldman M., Vanherweghem J.L. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int 1990, 38(5):982-984.
5. Verresen L., Waer M., Vanrenterghem Y., Michielsen P. Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet 1990, 336(8727):1360-1362.
6. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008, 26(6):669-675.
7. Maruyama T., Toida T., Imanari T., Yu G., Linhardt R.J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res 1998, 306(1-2):35-43.
8. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008, 358(23):2457-2467.
9. Ramacciotti E., Wahi R., Messmore H.L. Contaminated heparin preparations, severe adverse events and the contact system. Clin Appl Thromb Hemost 2008, 14(4):489-491.
10. Silverberg M., Diehl S.V. The activation of the contact system of human plasma by polysaccharide sulfates. Ann N Y Acad Sci 1987, 516:268-279.
11. van der Graaf F., Keus F.J., Vlooswijk R.A., Bouma B.N. The contact activation mechanism in human plasma: activation induced by dextran sulfate. Blood 1982, 59(6):1225-1233.
12. Cyr M., Lepage Y., Blais C., Gervais N., Cugno M., Rouleau J.L., et al. Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol 2001, 281(1):H275-H283.
13. Desormeaux A., Moreau M.E., Lepage Y., Chanard J., Adam A. The effect of electronegativity and angiotensin-converting enzyme inhibition on the kinin-forming capacity of polyacrylonitrile dialysis membranes. Biomaterials 2008, 29(9):1139-1146.
14. Krieter D.H., Grude M., Lemke H.D., Fink E., Bonner G., Scholkens B.A., et al. Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin. Kidney Int 1998, 53(4):1026-1035.
15. Keire D.A., Trehy M.L., Reepmeyer J.C., Kolinski R.E., Ye W., Dunn J., et al. Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate. J Pharm Biomed Anal 2010, 51(4):921-926.
16. Trehy M.L., Reepmeyer J.C., Kolinski R.E., Westenberger B.J., Buhse L.F. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities. J Pharm Biomed Anal 2009, 49(3):670-673.
17. Decarie A., Drapeau G., Closset J., Couture R., Adam A. Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides 1994, 15(3):511-518.
18. Raymond P., Drapeau G., Raut R., Audet R., Marceau F., Ong V., et al. Quantification of des-Arg9-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation. J Immunol Methods 1995, 180(2):247-257.
19. Blais C., Marc-Aurele J., Simmons W.H., Loute G., Thibault P., Skidgel R.A., et al. Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides 1999, 20(4):421-430.
20. Moreau M.E., Thibault L., Desormeaux A., Chagnon M., Lemieux R., Robillard P., et al. Generation of kinins during preparation and storage of whole blood-derived platelet concentrates. Transfusion 2007, 47(3):410-420.
21. Bawolak M.T., Gera L., Morissette G., Stewart J.M., Marceau F. B-9972 (D-Arg-[Hyp3, Igl5, Oic7, Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3, Igl5, D-Igl7, Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation. J Pharmacol Exp Ther 2007, 323(2):534-546.
22. Pruneau D., Paquet J.L., Luccarini J.M., Defrene E., Fouchet C., Franck R.M., et al. Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist. Immunopharmacology 1999, 43(2-3):187-194.
23. Bachvarov D.R., Houle S., Bachvarova M., Bouthillier J., Adam A., Marceau F. Bradykinin B(2) receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates. J Pharmacol Exp Ther 2001, 297(1):19-26.
24. Rice J. Mathematical statistics and data analysis 1995, Dulbury Press, Belmont.
25. Nuijens J.H., Huijbregts C.C., Eerenberg-Belmer A.J., Abbink J.J., Strack van Schijndel R.J., Felt-Bersma R.J., et al. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood 1988, 72(6):1841-1848.
26. Wuillemin W.A., te Velthuis H., Lubbers Y.T., de Ruig C.P., Eldering E., Hack C.E. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol 1997, 159(4):1953-1960.
27. Adam A., Albert A., Boulanger J., Genot D., Demoulin A., Damas J. Influence of oral contraceptives and pregnancy on constituents of the kallikrein-kininogen system in plasma. Clin Chem 1985, 31(9):1533-1536.
28. Adam A., Azzouzi M., Boulanger J., Ers P., Albert A., Damas J., et al. Optimized determination of plasma prokallikrein on a Hitachi 705 analyser. J Clin Chem Clin Biochem 1985, 23(4):203-207.
29. Blossom D.B., Kallen A.J., Patel P.R., Elward A., Robinson L., Gao G., et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008, 359(25):2674-2684.
30. Decarie A., Adam A., Couture R. Effects of captopril and icatibant on bradykinin (BK) and des [Arg9] BK in carrageenan-induced edema. Peptides 1996, 17(6):1009-1015.
31. Molinaro G., Gervais N., Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke 2002, 33(6):1712-1716.
32. Carranza Y.E., Anderson D., Doctor V. Effect of oversulfated chondroitin-6-sulfate or oversulfated fucoidan in the activation of glutamic plasminogen by tissue plasminogen activator: role of lysine and cyanogen bromide-fibrinogen. Blood Coagul Fibrinolysis 2008, 19(1):60-65.
33. Carranza Y.E., Durand-Rougley C., Doctor V. Effect of oversulfation on the chemical and biological properties of chondroitin-4-sulfate. Blood Coagul Fibrinolysis 2008, 19(6):483-487.
34. Renaux J.L., Thomas M., Crost T., Loughraieb N., Vantard G. Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. Kidney Int 1999, 55(3):1097-1103.
35. Baglin T., Barrowcliffe T.W., Cohen A., Greaves M. Guidelines on the use and monitoring of heparin. Br J Haematol 2006, 133(1):19-34.
36. Adam A., Desormeaux A., Moreau M.E. Bull Acad Natl Med 2007, 191(7):1443-1444.
37. Sabourin T., Guay K., Houle S., Bouthillier J., Bachvarov D.R., Adam A., et al. Absence of ligand-induced regulation of kinin receptor expression in the rabbit. Br J Pharmacol 2001, 133(7):1154-1162.
38. Liu H., Zhang Z., Linhardt R.J. Lessons learned from the contamination of heparin. Nat Prod Rep 2009, 26(3):313-321.